Why These Drugs Are So Expensive — And Why That's Not Changing Soon
GLP-1 medications currently cost up to $766 per month net of discounts and rebates — with out-of-pocket costs running $900 to $1,300 monthly for employees without coverage. That's not a one-time expense. Patients typically need to stay on these drugs continuously to maintain weight loss, meaning the cost commitment is ongoing rather than episodic.
Novo Nordisk has announced a list price reduction for Wegovy and Ozempic to $675 per month starting January 2027, and oral formulations now in development may bring costs down further over time. But today's pricing environment means that every employee who starts a GLP-1 for weight management adds a significant, recurring line to your pharmacy budget.
Adding GLP-1 coverage for weight management raises total pharmacy costs by 2 to 5 percent on average — and up to 10 to 15percent in high-utilization groups. For a self-funded employer spending $3million annually on pharmacy, that's a potential $90,000 to $450,000 addition depending on workforce demographics and how broadly coverage is written.
The Coverage Decision Is More Complicated Than It Looks
Most employers already cover GLP-1s for Type 2 diabetes — that's been standard for years. The decision that's causing the real tension is whether to extend coverage to weight management for employees without a diabetes diagnosis. That decision turns out to have a few layers most employers don't think about when they're first considering it.
The first is utilization. Employers who have expanded GLP-1 coverage for weight loss consistently report that uptake was higher than expected. The KFF 2025 Employer Health Benefits Survey found that many large employers who covered these drugs for weight loss are now scaling back or tightening criteria because actual utilization outpaced projections. Once employees know coverage is available, demand moves fast.
The second is adherence. Nearly two-thirds of patients discontinue GLP-1 treatment before reaching the 12-week mark needed for meaningful weight loss. For self-funded employers, that means paying for medications that aren't generating the health outcomes that might justify the cost over time.
The third is legal exposure. Coverage decisions around GLP-1s increasingly touch ADA considerations. Several courts and the EEOC have taken the position that severe obesity can be a disability under the ADA. If your plan covers GLP-1s for diabetes but excludes them for obesity, you may face nondiscrimination questions, particularly if employees can show that obesity is an underlying condition connected to other covered diagnoses. This is an evolving area and worth reviewing with legal counsel before finalizing your approach.
What Self-Funded Employers Can Actually Do
Here's where self-funded employers have an advantage over their fully insured counterparts. You can design your GLP-1 coverage strategy rather than accepting whatever the carrier defaults to. That means several levers are available to you.
Cost of an open-ended GLP-1 policy. Employers who cover GLP-1s for weight management with open-ended policies are paying a heavy price. Without documented BMI thresholds, required proof of prior lifestyle intervention attempts, or physician attestation of medical necessity, plan costs expand rapidly and largely unchecked. Coverage flows to a far broader population than clinical evidence supports, and without prior authorization as a checkpoint, there is no mechanism to ensure the medication is being used appropriately. This isn't about providing access — it's about writing a blank check.
Step therapy requirements. Requiring employees to attempt lower-cost alternatives or structured lifestyle interventions before accessing GLP-1s is both clinically defensible and cost-effective. It also creates a documented record that matters if coverage decisions are ever challenged.
Behavioral program requirements. Some employers are conditioning GLP-1 coverage on concurrent enrollment in nutrition or lifestyle coaching programs. The rationale is straightforward: the drugs work better with behavioral support, and adherence rates improve with structured engagement. This also creates a mechanism to identify employees who stop the medication early so resources can be redirected.
Formulary management with your PBM. GLP-1s are not classified as specialty drugs, even though their costs rival specialty pricing. That means they're often filling at standard retail or mail-order pharmacies without the utilization management that specialty drugs receive. Working with your PBM to add formulary controls specific to GLP-1s, separate from your general pharmacy formulary management, is worth the conversation.
Monitoring the pipeline. The GLP-1 landscape is moving fast. Oral formulations are arriving.Next-generation drugs combining multiple receptor pathways are in late-stage trials. Medicare coverage is expanding in 2027 under the BALANCE Model. Each of these shifts will affect your workforce's expectations and your plan's cost exposure. Building a regular review cadence into your pharmacy strategy, not just annual renewal, is the right posture for this category.
The Harder Question: Is Covering These Drugs Worth It?
This is the question every CFO eventually asks, and it deserves a straight answer.
The clinical case for GLP-1s extends beyond weight loss. Wegovy has FDA approval to reduce the risk of cardiovascular events, heart attack, stroke, cardiovascular death, in adults with obesity or overweight who have existing cardiovascular disease. For a self-funded employer whose highest-cost claims are often cardiovascular, that's not an irrelevant data point.
Whether the long-term reduction in downstream claims justifies the near-term pharmacy cost is genuinely uncertain and will vary significantly by workforce. A manufacturing workforce with a higher prevalence of obesity and cardiovascular risk may see a different return on GLP-1 investment than a younger, lower-risk population.
What is clear is that doing nothing is also a decision, and one that's getting harder to defend as employee awareness of these drugs grows and as more employers add coverage. The right answer isn't automatic coverage or automatic exclusion. It's a coverage design that reflects your actual population's risk profile, your plan's financial position, and a clear-eyed view of both the clinical evidence and the cost exposure.
That kind of analysis is what root cause benefits consulting is built for.
Not sure how to approach GLP-1 coverage for your workforce? Contact us for a complimentary benefits strategy assessment. We'll help you build a GLP-1 coverage strategy that's grounded in your actual claims data — not just what everyone else is doing.
About the Author: Genesys Health specializes in root cause benefits consulting for self-funded employers. We work with organizations of all shapes and sizes — from manufacturers and family offices to PE-backed companies and beyond — helping them transform benefits from a line item into a strategic asset.
